Hims & Hers Health Inc. Stock News

Hims & Hers (HIMS -7.84%) is adding another specialty in an effort to build out its healthcare platform. The company has brought testosterone to the market, the first big addition since weight loss in 2023.

PHILADELPHIA , Sept. 15, 2025 /PRNewswire/ -- Berger Montague, a national securities litigation law firm, advises shareholders of Hims & Hers Health Inc. ("Hims & Hers" or the "Company") (NYSE: HIMS) about an investigation into Hims & Hers' Board of Directors for potential breaches of fiduciary duties to the Company and its shareholders in connection with Novo Nordisk A/S's termination of its p...

U.S. Food and Drug Administration Commissioner Martin Makary said on Friday that Hims & Hers' Super Bowl advertisement breached federal law as it highlighted the benefits of weight-loss drugs without mentioning side effects.

Hims is now a GARP stock, combining rapid revenue and subscriber growth with a lower, fair valuation after a recent selloff. The company's scalable model, product launches, and global expansion plans support management's ambitious 2030 revenue and EBITDA targets. The stock trades at a reasonable historical and forward-looking valuation. A potential interim bottom and a near-term rebound are bot...

RALEIGH, N.C., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals, Inc. today announced a collaboration with Hims & Hers™, one of the largest digital health platforms for men, to make KYZATREX® , an FDA-approved oral testosterone replacement therapy for adult men with low or no testosterone levels due to certain medical conditions, available to patients through the Hims & Hers platform i...

Hims stock popped Wednesday after the telemedicine giant announced its long-awaited foray into offering testosterone replacement therapy.

Revenue is scaling rapidly, from $150M in 2020 to ~$2.3B expected in 2025. Over 90% of revenue is recurring subscriptions, ensuring stability and visibility. The vertically integrated model builds a brand moat and delivers 76% gross margins.

Hims & Hers Health said on Wednesday it is launching a new category in men's health, offering access to personalized treatment plans for low testosterone.